Stocks
Arrowhead Pharmaceuticals (ARWR) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 65.6 | -87.2 | -132.6 | -162.3 | -175.7 | -508.3 | ||
| Changes by years, y/y, % | -227% | -233% | +52% | +22% | +8% | +27.7% | |||
Arrowhead Pharmaceuticals. EBITDA US GAAP, bln rub
Arrowhead Pharmaceuticals. EBITDA US GAAP, changes, %
Arrowhead Pharmaceuticals. EBITDA US GAAP, sum by quarters, bln rub
Arrowhead Pharmaceuticals (ARWR) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -95.0 | -99.9 | -129.1 | -115.2 | -164.1 | -508.3 | |
| Changes by years, y/y, % | +35% | +19% | +206% | -308% | +73% | |||
| Changes by quarters, q/q, % | -271% | +5% | +29% | -11% | +42% | |||
